An international randomized control trial to compare targeted intraoperative radiotherapy (TARGIT) and conventional post-operative radiotherapy after conservative breast surgery for women with early stage breast cancer. The main study findings were published in June 2020, showing TARGIT to be equal to conventional post-operative radiotherapy in terms of local control, breast cancer specific survival and overall survival. More study finding will soon be published.
A prospective nonrandomized trial designed to determine if patients with pure DCIS are considered eligible for concurrent IORT based on preoperative mammography and CE-MRI could be successfully treated using IORT with minimal need for additional therapy due to inadequate surgical margins or excessive tumor size. Interim study results have been published but long-term patient follow-up continues. See the link below for the online study abstract. The full length paper is available upon request.
A phase IV pragmatic registry trial that studies the side effects of targeted intraoperative radiation therapy and how well it works in treating patients with early stage breast cancer following breast conserving surgery in patients in the United States. Enrollment is complete. Patient follow-up is ongoing.
An international randomized controlled trial to compare targeted intra-operative radiotherapy boost with conventional external beam radiotherapy boost after lumpectomy for breast cancer in women with a high risk of local recurrence. The study is currently enrolling.
A phase II, non-randomized trial to examine the use of cryoablation as an alternative to surgery in the treatment of early stage invasive breast cancer. The hypothesis is that cryoablation will complete ablation and destroy the tumor in a selected population of women who may otherwise be adequately treated with surgery. The study is currently enrolling.
The Target Collaborative Group's Quality Improvement Initiative is a prospective patient registry that aims to improve the quality and safety of care of patients treated with breast conserving surgery and TARGIT; enable longitudinal patient outcomes analysis and reporting; facilitate development of “best practices” related to BCS and TARGIT; enable decision support and care pathways to enhance patient care and safety; and facilitate value-based healthcare. The registry is ongoing.
Copyright © 2021 Helen Rey Breast Cancer Research Foundation - All Rights Reserved.
Founded in 2017